Intra-Cellular Therapies, Inc. Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc.

ITCI

Rangering i aksjer #1692
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Aksjekurs
$131.87
Sist synkronisert: 2025-04-02
Markedsverdi
$12.68B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Intra-Cellular Therapies, Inc. (ITCI)

Kategori

Healthcare
Utbyttehistorikk for Intra-Cellular Therapies, Inc. (ITCI)
Intra-Cellular Therapies, Inc. (aksjesymbol: ITCI) har gitt totalt 0 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Utbyttebetalinger for Intra-Cellular Therapies, Inc. (ITCI) fra 2026 til 2026
Årlige utbyttebetalinger
År Utbytte (justert for aksjesplitt) Endre
Ikke nok data for de angitte datoene.
Liste over alle utbyttebetalinger
År Utbytte Endre
Ikke nok data for de angitte datoene.
Utbyttebetalinger for lignende selskaper eller konkurrenter